دورية أكاديمية
أعرض في EDS

COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.

التفاصيل البيبلوغرافية
العنوان: COVID-19 pandemic in Saint Petersburg, Russia: Combining population-based serological study and surveillance data.
المؤلفون: Barchuk A; European University at St. Petersburg, St. Petersburg, Russia.; Petrov National Research Medical Center of Oncology, Pesochny, St. Petersburg, Russia., Skougarevskiy D; European University at St. Petersburg, St. Petersburg, Russia., Kouprianov A; Independent Researcher, St. Petersburg, Russia., Shirokov D; Clinic 'Scandinavia' (LLC Ava-Peter), St. Petersburg, Russia., Dudkina O; European University at St. Petersburg, St. Petersburg, Russia., Tursun-Zade R; European University at St. Petersburg, St. Petersburg, Russia., Sergeeva M; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Tychkova V; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Komissarov A; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Zheltukhina A; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Lioznov D; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia., Isaev A; Center of Genetics and Reproductive Medicine GENETICO LLC, Moscow, Russia.; Human Stem Cells Institute, Moscow, Russia., Pomerantseva E; Center of Genetics and Reproductive Medicine GENETICO LLC, Moscow, Russia., Zhikrivetskaya S; Center of Genetics and Reproductive Medicine GENETICO LLC, Moscow, Russia., Sofronova Y; Center of Genetics and Reproductive Medicine GENETICO LLC, Moscow, Russia., Blagodatskikh K; Center of Genetics and Reproductive Medicine GENETICO LLC, Moscow, Russia., Titaev K; European University at St. Petersburg, St. Petersburg, Russia., Barabanova L; Clinic 'Scandinavia' (LLC Ava-Peter), St. Petersburg, Russia., Danilenko D; Smorodintsev Research Institute of Influenza, St. Petersburg, Russia.
المصدر: PloS one [PLoS One] 2022 Jun 15; Vol. 17 (6), pp. e0266945. Date of Electronic Publication: 2022 Jun 15 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
أسماء مطبوعة: Original Publication: San Francisco, CA : Public Library of Science
مواضيع طبية MeSH: COVID-19*/epidemiology , SARS-CoV-2*, Adult ; Antibodies, Viral ; Bayes Theorem ; Humans ; Pandemics ; Seroepidemiologic Studies
مستخلص: Background: The COVID-19 pandemic in Russia has already resulted in 500,000 excess deaths, with more than 5.6 million cases registered officially by July 2021. Surveillance based on case reporting has become the core pandemic monitoring method in the country and globally. However, population-based seroprevalence studies may provide an unbiased estimate of the actual disease spread and, in combination with multiple surveillance tools, help to define the pandemic course. This study summarises results from four consecutive serological surveys conducted between May 2020 and April 2021 at St. Petersburg, Russia and combines them with other SARS-CoV-2 surveillance data.
Methods: We conducted four serological surveys of two random samples (May-June, July-August, October-December 2020, and February-April 2021) from adults residing in St. Petersburg recruited with the random digit dialing (RDD), accompanied by a telephone interview to collect information on both individuals who accepted and declined the invitation for testing and account for non-response. We have used enzyme-linked immunosorbent assay CoronaPass total antibodies test (Genetico, Moscow, Russia) to report seroprevalence. We corrected the estimates for non-response using the bivariate probit model and also accounted the test performance characteristics, obtained from independent assay evaluation. In addition, we have summarised the official registered cases statistics, the number of hospitalised patients, the number of COVID-19 deaths, excess deaths, tests performed, data from the ongoing SARS-CoV-2 variants of concern (VOC) surveillance, the vaccination uptake, and St. Petersburg search and mobility trends. The infection fatality ratios (IFR) have been calculated using the Bayesian evidence synthesis model.
Findings: After calling 113,017 random mobile phones we have reached 14,118 individuals who responded to computer-assisted telephone interviewing (CATI) and 2,413 provided blood samples at least once through the seroprevalence study. The adjusted seroprevalence in May-June, 2020 was 9.7% (95%: 7.7-11.7), 13.3% (95% 9.9-16.6) in July-August, 2020, 22.9% (95%: 20.3-25.5) in October-December, 2021 and 43.9% (95%: 39.7-48.0) in February-April, 2021. History of any symptoms, history of COVID-19 tests, and non-smoking status were significant predictors for higher seroprevalence. Most individuals remained seropositive with a maximum 10 months follow-up. 92.7% (95% CI 87.9-95.7) of participants who have reported at least one vaccine dose were seropositive. Hospitalisation and COVID-19 death statistics and search terms trends reflected the pandemic course better than the official case count, especially during the spring 2020. SARS-CoV-2 circulation showed rather low genetic SARS-CoV-2 lineages diversity that increased in the spring 2021. Local VOC (AT.1) was spreading till April 2021, but B.1.617.2 substituted all other lineages by June 2021. The IFR based on the excess deaths was equal to 1.04 (95% CI 0.80-1.31) for the adult population and 0.86% (95% CI 0.66-1.08) for the entire population.
Conclusion: Approximately one year after the COVID-19 pandemic about 45% of St. Petersburg, Russia residents contracted the SARS-CoV-2 infection. Combined with vaccination uptake of about 10% it was enough to slow the pandemic at the present level of all mitigation measures until the Delta VOC started to spread. Combination of several surveillance tools provides a comprehensive pandemic picture.
Competing Interests: Anton Barchuk reports personal fees from AstraZeneca, MSD, and Biocad outside the submitted work. Artur Isaev, Ekaterina Pomerantseva and Svetlana Zhikrivetskaya report a pending patent for the test system (ELISA) for detecting antibodies specific to the SARS-COV-2 in a biological sample. Other authors have no conflict of interest to declare. This does not alter our adherence to PLOS One policies on sharing data and materials. It also complies with the manuscript submission guidelines of PLOS One.
References: Lancet. 2021 Jun 26;397(10293):2461-2462. (PMID: 34139198)
J Med Virol. 2021 Oct;93(10):5846-5852. (PMID: 34081328)
Lancet. 2020 Aug 1;396(10247):313-319. (PMID: 32534626)
Cell Rep Med. 2021 Jul 20;2(7):100354. (PMID: 34250512)
Nat Commun. 2021 Feb 10;12(1):905. (PMID: 33568663)
Eur J Epidemiol. 2020 Apr;35(4):331-333. (PMID: 32318914)
Lancet Glob Health. 2021 May;9(5):e598-e609. (PMID: 33705690)
BMJ. 2021 May 19;373:n1137. (PMID: 34011491)
Dtsch Arztebl Int. 2021 Dec 3;118(48):824-831. (PMID: 35191825)
BMJ. 2020 Nov 27;371:m4509. (PMID: 33246972)
Signif (Oxf). 2021 Feb;18(1):16-19. (PMID: 33821160)
PLoS One. 2020 Nov 9;15(11):e0241468. (PMID: 33166301)
N Engl J Med. 2019 Dec 26;381(26):2569-2580. (PMID: 31881145)
Sci Rep. 2021 Jun 21;11(1):12930. (PMID: 34155259)
Lancet Public Health. 2020 May;5(5):e289-e296. (PMID: 32330458)
Diabetes Metab Res Rev. 2022 Jan;38(1):e3465. (PMID: 33955644)
Nat Commun. 2021 Jan 28;12(1):649. (PMID: 33510171)
Virus Evol. 2022 Mar 05;8(1):veac017. (PMID: 35371558)
Sci Rep. 2020 Nov 25;10(1):20527. (PMID: 33239650)
Int J Infect Dis. 2020 Jun;95:192-197. (PMID: 32305520)
Elife. 2021 Jun 30;10:. (PMID: 34190045)
JAMA Intern Med. 2021 May 1;181(5):672-679. (PMID: 33625463)
Lancet. 2020 Aug 22;396(10250):535-544. (PMID: 32645347)
المشرفين على المادة: 0 (Antibodies, Viral)
SCR Organism: SARS-CoV-2 variants
تواريخ الأحداث: Date Created: 20220615 Date Completed: 20220617 Latest Revision: 20220716
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC9200332
DOI: 10.1371/journal.pone.0266945
PMID: 35704649
قاعدة البيانات: MEDLINE
الوصف
تدمد:1932-6203
DOI:10.1371/journal.pone.0266945